Abstract
Isoprenoid molecules are formed through a complex, multi-enzyme synthetic pathway. Main products of this pathway are cholesterol, bile acid and steroids. In addition, there are minor products of the pathway, such as dolichol, isopentenyl adenosine and ubiquinone. The early rate limiting step in all isoprenoid synthesis is the formation of mevalonate catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Potent and specific competitive inhibitors of HMG-CoA reductase have been identified, which can block mevalonate formation and reduce cholesterol and other isoprenoid production. For example, mevinolin and several of its derivatives are increasingly being used clinically for treatment of hypercholesterolemia, particularly with view to improvement of cardiovascular disease (1,2,3).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
J. M. Hoeg and H. B. Brewer, Jr., 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the treatment of hypercholesterolemia, JAMA258:3532 (1987).
The Lovastatin Study Group III, A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia, JAMA260:359 (1988).
S. M. Grundy, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, New Engl. J. Med. 319:24 (1988).
R. B. Herberman, ed., Natural cell-mediated immunity against tumors, Academic Press, New York, London (1980).
R. B. Herberman, ed., NK cells and other natural effector cells, Academic Press, New York, London (1982).
R. B. Herberman and D. M. Callewaert, Mechanisms of Cytotoxicity by NK cells, Academic Press, New York, London (1985).
J. R. Ortaldo, L. Mason, J. P. Gerari, L. E. Henderson, W. Farrar, R. F. Hopkins III, R. B. Herberman, and H. Rabin, Effects of natural and recombinant IL-2 on regulation of IFN gamma production and natural killer activity: Lack of involvement of the TAC antigen for these immunoregula-tory events, Immunol. 133:799 (1984).
A. E. Grimm, A. Mazumder, H. Z. Zhang, and S. A. Rosenberg, Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes, J. Exp. Med. 155:1823 (1982).
A. E. Grimm and S. A. Rosenberg, The human lymphokine activated killer cell phenomenon, Lymphokines 9:279 (1984).
A. E. Grimm, R. J. Robb, J. A. Roth, L. M. Neckers, L. B. Lachman, D. J. Wilson, and S. A. Rosenberg, Lymphokine-activated killer cell phenomenon, III, Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells, J. Exp. Med. 158:1356 (1983).
S. A. Rosenberg, Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans, J. Clin. Oncol. 6:403 (1988).
C. M. van Haelst-Pisani, R. J. Pisani, and J. S. Kovach, Cancer immunotherapy: Current status of treatment with interleukin 2 and lymphokine-activated killer cells, Mayo Clin. Proc. 64:451 (1989).
R. A. Schmidt, C. J. Schneider, and J. A. Glomset, Evidence for post-translation of a product of mevalonic acid into swiss 3T3 cell proteins, J. Biol. Chem. 259:10175 (1984).
L. A. Beck, T. J. Hosick, and M. Sinensky, Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei, J. Cell. Bid. 107:1307 (1988).
E. M. Repko, and W. A. Maltese, Post-translational isoprenylation of cellular proteins is altered in response to mevalonate availability, J. Biol. Chem. 264:9945 (1989).
J. F. Hancock, A. I. Magee, J. E. Childs, and C. J. Marshall, AII ras proteins are polyisoprenylated but only some are palmitoylated, Cell 57:1167 (1989).
J. A. Glomset, M. H. Gelb, and C. C. Farnsworth, Prenylprotein in eukaryotic cells: A new type of membrane anchor TIBS 15:139 (1990).
I. Kaneko, Y. Hazama-Shimada and A. Endo, Inhibitory effects of lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, Eur. J. Biochem. 87:313 (1978).
P. Anderson, M. Caliguiri, J. Ritz, and S. F. Schlossman, CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex, Nature341:159 (1989).
W. J. Leonard, J. M. Depper, M. Kronke, R. J. Robb, T. A. Waldmann, and W. C. Greene, The human receptor for T-cell growth factor, J. Biol. Chem. 260:1872 (1985).
M. C. Miedel, J. D. Hulmes, D. V. Weber, P. Bailon, and Y-C. E. Pan, Structural analysis of recombinant soluble human interleukin-2 receptor, Bio-chem. Biophys. Res. Comm. 154:372 (1988).
M. Tsudo, C. K. Goldman, K. F. Bongiovanni, W. C. Chan, E. F. Winton, M. Yagita, E. A. Grimm, and T. A. Waldmann, The p75 peptide is the receptor for interleukin 2 on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells, Proc. Natl. Acad. Sci. USA 84:5394 (1987).
G. A. Reynolds, S. K. Basu, T. F. Osborne, D. J. Chin, G. Gil, M. S. Brown, J. L. Goldstein, and K. L. Luskey, HMG-CoA reductase: A negatively regulated gene with unusual promoter and 5’ untranslated regions, Cell 38:275 (1984).
T. F. Osborne, J. L. Goldstein, and M. S. Brown, 5’ End of HMG-CoA reductase gene contains sequences responsible for cholesterol-mediated inhibition of transcription, Cell 42:203 (1985).
T. F. Osborne, G. Gil, M. S. Brown, R. C. Kowal, and J. L. Goldstein, Identification of promoter element required for in vitro transcription of hamster 3-hydroxy-3-methylglutaryl coenzyme A reductase gene, Proc. Natl. Acad. Sci. USA 84:3614 (1987).
A. A. Kandutsch, H. W. Chen, and J. J. Heiniger, Biological activity of some oxygenated sterols, Science 201:498 (1978).
H. W. Chen, The role of cholesterol metabolism in cell growth, Fed. Proc. 43:126 (1984).
H. W. Chen, H. J. Heiniger, and A. A. Kandutsch, Stimulation of sterol and DNA synthesis in leukemic blood cells by low concentrations of phyto-hemagglutinin, Expt. Cell. Res. 109:253 (1977).
H. M. K. Humphries and H. M. McConnell, Potent immunosuppression by oxidized cholesterol, J. Immunol. 122:121 (1979).
H. M. K. Humphries, Compactin and oxidized cholesterol, both known to inhibit cholesterol biosynthesis differ in their ability to suppress in vitro immune responses, Cancer Res. 41:3789 (1981).
H. J. Heiniger and D. Marshall, Oxygenated derivatives of cholesterol and lymphocyte function: Cholesterol synthesis in polyclonally activated cytotoxic lymphocytes and its requirement for differentiation and proliferation, Proc. Natl. Acad. Sd. USA 79:3823 (1982).
H. J. Heininger, H. W. Chen, G. A. Boissonneault, M. Hess, H. Cottier, and R. D. Stoner, The role of cholesterol and oxysterols in lymphocyte proliferation and differentiation, Ann. NY Acad. Sci. 459:111 (1985).
W. R. Schafer, R. Kim, R. Sterne, J. Thorner, S.-H. Kim, and J. Rine, Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans, Science 245:379 91989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Linna, J., Moke, M., Chen, H.W. (1991). Isoprenoid Formation and Cell-Mediated Immunological Functions. In: Friedman, H., Specter, S., Klein, T.W. (eds) Drugs of Abuse, Immunity, and Immunodeficiency. Advances in Experimental Medicine and Biology, vol 288. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5925-8_31
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5925-8_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5927-2
Online ISBN: 978-1-4684-5925-8
eBook Packages: Springer Book Archive